Update in the treatment of brain metastases from lung cancer

Clinical Lung Cancer

Volumn 8, Issue 3, 2006, Pages 180-186

  Schwer, Amanda L ^a   Gaspar, Laurie E ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

Chemoradiation therapy; Prognostic factors; Surgery; Whole brain radiation therapy

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; GADOLINIUM TEXAPHYRIN; GEFITINIB; GEMCITABINE; HYDROXYUREA; IRINOTECAN; LOMUSTINE; METHOTREXATE; NAVELBINE; PROCARBAZINE; TEMOZOLOMIDE; TENIPOSIDE; THIOTEPA; TOPOTECAN; VINCRISTINE;

BLOOD BRAIN BARRIER; BRAIN METASTASIS; BRAIN RADIATION; BRAIN SCINTISCANNING; BRAIN SURGERY; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL FEATURE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; GAMMA KNIFE RADIOSURGERY; HUMAN; INTERMETHOD COMPARISON; LUNG CANCER; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; RECURRENCE RISK; REVIEW; RISK ASSESSMENT; STEREOTAXIC SURGERY; SURGICAL EQUIPMENT; SURVIVAL RATE; SURVIVAL TIME;

EID: 33845406670     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2006.n.045     Document Type: Review

References (80)

1. Davey P. Brain metastases: treatment options to improve outcomes. CNS Drugs 2002; 16:325-338.
2. Newton HB. Chemotherapy for the treatment of metastatic brain tumors. Expert Rev Anticancer Ther 2002; 2:495-506. Review.
3. Patchell RA. The management of brain metastases. Cancer Treat Rev 2003; 29:533-540.
4. Ryan GF, Ball DL, Smith JG. Treatment of brain metastases from primary lung cancer. Int J Radiat Oncol Biol Phys 1995; 31:273-278.
5. Stuschke M, Eberhardt W, Pottgen C, et al. Prophylactic cranial irradiation in locally advanced non-small-cell lung cancer after multimodality treatment: long-term follow-up and investigations of late neuropsychologic effects. J Clin Oncol 1999; 17:2700-2709.
6. Gaspar LE, Chansky K, Albain KS, et al. Time from treatment to subsequent diagnosis of brain metastases in stage III non-small cell lung cancer: a retrospective review by the Southwest Oncology Group. J Clin Oncol 2005; 23:2955-2961.
7. Norden AD, Wen YW, Kesari S. Brain metastases. Curr Opin Neurol 2005: 18:654-661.
8. Gaspar L, Scott C, Rotman M, et al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trial. Int J Radiat Oncol Biol Phys 1997; 37:745-751.
9. Nathoo N, Toms SA, Barnett GH. Metastases to the brain: current management perspectives. Expert Rev Neurother 2004; 4:633-640.
10. Ettinger D, Johnson B. Update: NCCN small cell and non-small cell lung cancer Clinical Practice Guidelines. J Natl Compr Canc Netw 2005; 3(suppl 1):S17-S21.
11. Silvestri GA, Tanoue LT, Margolis ML, et al. The noninvasive staging of non-small cell lung cancer: the guidelines. Chest 2003; 123:147S-156S.
12. Earnest F, Ryu JH, Miller GM, et al. Suspected non-small cell lung cancer: incidence of occult brain and skeletal metastases and effectiveness of imaging for diagnosis-pilot study. Radiology 1999; 211:137-145.
13. Hooper RG, Tenholder MF, Underwood GH, et al. Computed tomographic scanning of the brain in initial staging of bronchogenic carcinoma. Chest 1984; 85:774-776.
14. Ichinose Y, Hara N, Ohta M, et al. Preoperative examination to detect distant metastasis is not advocated for asymptomatic patients with stages I and II non-small cell lung cancer. Preoperative examination for lung cancer. Chest 1989; 96:1104-1109.
15. Schellinger PD, Meinck HM, Thron A. Diagnostic accuracy of MRI compared to CCT in patients with brain metastases. J Neurooncol 1999; 44:275-281.
16. Kaal ECA, Taphoorn JB, Vecht CJ. Symptomatic management and imaging of brain metastases. J Neurooncol 2005; 75:15-20.
17. Suzuki K, Yamamoto M, Hasegawa Y, et al. Magnetic resonance imaging and computed tomography in the diagnoses of brain metastases of lung cancer. Lung Cancer 2004; 46:357-360.
18. Rohren EM, Provenzale JM, Barboriak DP, et al. Screening for cerebral metastases with FDG PET in patients undergoing whole-body staging of non-central nervous system malignancy. Radiology 2003; 226:181-187.
19. Rodrigus P, de Brouwer P, Raaymakers E. Brain metastases and non-small cell lung cancer. Prognostic factors and correlation with survival after irradiation. Lung Cancer 2001; 32:129-136.
20. Tang SG, Tseng C, Tsay R et al. Fredicton for patterms of brain relapse and overall survival in patients with non-small cell lung cancer. J Neurooncol 2005; 73:153-161.
21. Flannery TW, Suntharalingam M, Kwok Y, et al. Gamma knife steteotactic radiosurgery for synchronous versus metachronous solitary brain metastases from non-small cell lung cancer. Lung Cancer 2003; 42:327-333.
22. Zabel A, Milker-Zabel S, Thilmann C, et al. Treatment of brain metastases in patients with non-small cell lung cancer (NSCLC) by stereotactic linac-based radiosurgery: prognostic factors. Lung Cancer 2002; 37:87-94.
23. Abrahams JM, Torchia M, Putt M, et al. Risk factors affecting survival after brain metastases from non-small cell lung carcinoma: a follow-up study of 70 patients. J Neurosurg 2001; 95:595-600.
24. Videtic GM, Reddy CA, Chao TW, et al. Do gender and race influence survival in patients with non-small cell lung cancer brain metastases? An outcomes study utilizing the RTOG RPA class stratification. J Clin Oncol 2006; 24(18 suppl):402s (Abstract #7153).
25. Coia LR, Aaronson N, Linggood R, et al. A report of the consensus workshop panel on the treatment of brain metastases. Int J Radiat Oncol Biol Phys 1992; 23:223-227.
26. Khuntia D, Brown P, Li J, et al. Whole-brain radiotherapy in the management of brain metastasis. J Clin Oncol 2006; 24:1295-1303.
27. Nieder C, Berberich W, Nestle U, et al. Relation between local result and total dose of radiotherapy for brain metastases. Int J Radiat Oncol Biol Phys 1995; 33:349-355.
28. Borgelt B, Gelber R, Kramer S, et al. The palliation of brain metastases: final results of the first two studies by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 1980; 6:1-9.
29. Murray KJ, Scott C, Greenberg HM, et al. A randomized phase III study of accelerated hyperfractionation versus standard in patients with unresected brain metastases: a report of the Radiation Therapy Oncology Group (RTOG) 9104. Int J Radiat Oncol Biol Phys 1997; 39:571-574.
30. Haie-Meder C, Pellae-Cosset B, Laplanche A, et al. Results of a randomized clinical trial comparing two radiation schedules in the palliative treatment of brain metastases. Radiother Oncol 1993; 26:111-116.
31. Shaw E, Scott C, Suh J, et al. RSR13 plus cranial radiation therapy in patients with brain metastases: comparison with the Radiation Therapy Oncology Group recursive portioning analysis brain metastases database. J Clin Oncol 2003; 21:2364-2371.
32. Nussbaum ES, Djalilian HR, Cho KH, et al. Brain metastases. Histology, multiplicity, surgery, and survival. Cancer 1996; 78:1781-1788.
33. Nieder C, Berberich W, Schnabel K. Tumor-related prognostic factors for remission of brain metastases after radiotherapy. Int J Radiat Oncol Biol Phys 1997; 39:25-30.
34. Penel N, Brichet A, Prevost B, et al. Prognostic factors of synchronous brain metastases from lung cancer. Lung Cancer 2001; 33:143-154.
35. Suh JH, Stea B, Nabid A, et al. Phase III study of efaproxiral as an adjunct to whole-brain radiation therapy for brain metastases. J Clin Oncol 2006; 24:106-114.
36. Rosenberg A, Knox S. Radiation sensitization with redox modulators: a promising approach. Int J Radiat Oncol Biol Phys 2006; 64:343-354.
37. Postmus PE, Haaxma-Reiche, Gregor A, et al. Brain-only metastases of small-cell lung cancer; efficacy of whole brain radiotherapy. An EORTC phase II study. Radiother Oncol 1998; 46:29-32.
38. Mehta MP, Shapiro WR, Glantz MJ, et al. Lead-in phase to randomized trial of motexafin gadolinium and whole brain radiation for patients with brain metastases: centralized assessment of magnetic resonance imaging, neurocognitive, and neurologic end points. J Clin Oncol 2003; 20:3445-3453.
39. Mehta MP, Rodrigus P, Terhaard CJ, et al. Survival and neurologic outcome in a randomized trial of motexafin gadolinium and whole-brain radiation therapy in brain metastases. J Clin Oncol 2003; 21:2529-2536.
40. Mehta MP, Gervais R, Chabot P, et al. Motexafin gadolinium (MGd) combined with prompt whole brain radiation therapy (RT) prolongs time to neurologic progression in non-small cell lung cancer (NSCLC) patients with brain metastases: results of a phase III trial. J Clin Oncol 2006; 24(18 suppl):367s (Abstract #7014).
41. Patchell RA, Tibbs PA, Walsh JW, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 1990; 322:494-500.
42. Vecht CJ, Haaxma-Reiche H, Noordijk EM, et al. Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery? Ann Neurol 1993; 33:583-590.
43. Mintz AH, Kestle J, Rathbone MP, et al. A randomized study to assess the efficacy of surgery in addition to radiotherapy in patients with a single cerebral metastasis. Cancer 1996; 78:1470-1476.
44. Patchell RA, Tibbs PA, Regine WF, et al. Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA 1998; 280:1485-1489.
45. Vogelbaum MA, Suh JH. Resectable brain metastases. J Clin Oncol 2006; 24:1289-1294.
46. Sills AK. Current treatment approaches to surgery for brain metastases. Neurosurg 2005; 57(suppl 4):S24-S32. Discussion S1-S4.
47. Chidel MA, Suh JH, Greskovich JF, et al. Treatment outcome for patients with primary nonsmall-cell lung cancer and synchronous brain metastasis. Radiat Oncol Investig 1999; 7:313-319.
48. Bonnette P, Puyo P, Gabriel C, et al. Surgical management of non-small cell lung cancer with synchronous brain metastases. Chest 2001; 119:1469-1475.
49. Billing PS, Miller DL, Allen MS, et al. Surgical treatment of primary lung cancer with synchronous brain metastases. J Thorac Cardiovasc Surg 2001; 122:548-553.
50. Daniels M, Wright GM. Complete resection of non-small cell lung cancer and oligo-metastatic brain disease. Aust N Z J Surg 2005; 75:963-966.
51. Quan AL, Videtic GM, Suh JH. Brain metastases in small cell lung cancer. Oncology 2004; 18:961-972.
52. Andrews DW, Scott CB, Sperduto PW, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 tandomised trial. Lancet 2004; 363:1665-1672.
53. Stafinski T, Jhangri GS, Yan E, et al. Effectiveness of stereotactic radiosurgery alone or in combination with whole brain radiotherapy compared to conventional surgery and/or whole brain radiotherapy for the treatment of one or more brain metastases: a systematic review and meta-analysis. Cancer Treat Rev 2006; 32:203-213.
54. Aoyama H, Shirato H, Tago M, et al. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for the treatment of brain metastases: a randomized controlled trial. JAMA 2006; 295:2483-2491.
55. Mehta MP, Tsao MN, Whelan TJ, et al. The American Society for Therapeutic Radiology and Oncology (ASTRO) evidence-based review of the role of radiosurgery for brain metastases. Int J Radiat Oncol Biol Phys 2005; 63:37-46.
56. Serizawa T, Ono J, Iichi T, et al. Gamma knife radiosurgery for metastatic brain tumors from lung cancer: a comparison between small cell and non-small cell carcinoma. J Neurosurg 2002; 97(suppl 5):484-488.
57. Sheehan J, Kondziolka D, Flickinger J, et al. Radiosurgery for patients with recurrent small cell lung carcinoma metastatic to the brain: outcomes and prognostic factors. J Neurosurg 2005; 102:247-254.
58. Langer CJ, Mehta MP. Current management of brain metastases, with a focus on systemic options. J Clin Oncol 2005; 23:6207-6219.
59. Peereboom DM. Chemotherapy in brain metastases. Neurosurgery 2005; 57:S54-S65. Review S1-S4.
60. Christodoulou C, Bafaloukoos D, Kosmidis P, et al. Phase II study of temozolomide in heavily pretreated cancer patients with brain metastases. Ann Oncol 2001; 12:249-254.
61. Abrey LE, Olson JD, Raizer JJ, et al. A phase II trial of temozolomide for patients with recurrent or progressive brain metastases. J Neurooncol 2001; 53:259-265.
62. Verger E, Gil M, Yaya R, et al. Temozolomide and concomitant whole brain radiotherapy in patients with brain metastases: a phase II randomized trial. Int J Radiat Oncol Biol Phys 2005; 61:185-191.
63. Antonadou D, Paraskevaidis M, Sarris G, et al. Phase II randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases. J Clin Oncol 2002; 20:3644-3650.
64. Malacarne P, Santini A, Maestri A. Response of brain metastases from lung cancer to systemic chemotherapy with carboplatin and etoposide. Oncology 2006; 53:210-213.
65. Franciosi V, Cocconi G, Michiara M, et al. Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, nonsmall cell lung carcinoma, or malignant melanoma: a prospective study. Cancer 1999; 85:1599-1605.
66. Minotti V, Crino L, Meacci ML, et al. Chemotherapy with cisplatin and teniposide for cerebral metastases in non-small cell lung cancer. Lung Cancer 1998; 20:93-98.
67. Quadvlieg V, Bosquee L, Gustin M, et al. Frontline gemcitabine and cisplatin based chemotherapy in patients with NSCLC inoperable brain metastases. Proc Am Soc Clin Oncol 2004; 22(14 suppl):642 (Abstract #7117).
68. Robinet G, Thomas P, Breton JL, et al. Results of a phase III study of early versus delayed whole brain radiotherapy with concurrent cisplatin and vinotelbine combination in inoperable brain metastasis of non-small-cell lung cancer: Groupe Francais de Pneumo-Cancerologie (GFPC) Protocol 95-1. Ann Oncol 2001; 12:59-67.
69. Postmus PE, Smit EF, Haaxma-Reiche H, et al. Teniposide for brain metastases of small-cell lung cancer: a phase II study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 1995; 13:660-665.
70. Korfel A, Oehm C, von Pawel J, et al. Response to topotecan of symptomatic brain metastases of small-cell lung cancer after whole brain irradiation: a multicentre phase II study. Eur J Cancer 2002; 38:1724-1729.
71. Postmus PE, Haaxma-Reiche H, Smit EF, et al. Treatment of brain metastases of small-cell lung cancer: comparing teniposide and teniposide with whole-brain radiotherapy- a phase III study of the European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 2000; 18:3400-3408.
72. Twelves CJ, Souhami RL, Harper PG, et al. The response of cerebral metastases in small cell lung cancer to systemic chemotherapy. Br J Cancer 1990; 61:147-150.
73. Tummarello D, Lippe P, Bracci R, et al. First line chemotherapy in patients with brain metastases from non-small and small cell lung cancer. Oncol Reports 1998; 5:897-900.
74. Humblet Y, Weynants P, Bosly A, et al. Carboplatin in association with etoposide and either adriamycin or epirubicin for untreated small cell lung cancer: a dose escalation study of carboplatin. UCL Clinical Oncology Group. Medical Oncol Tumor Pharmacother 1989; 6:207-212.
75. Seute T, Leffers P, Wilmink JT, et al. Response of asymptomatic brain metastases from small-cell lung cancer to systemic first-line chemotherapy. J Clin Oncol 2006 24:2079-2083.
76. Hotta K, Kiura K, Ueoka H, et al. Effect of gefitinib ("Iressa", ZD1839) on brain metastases in patients with advanced non-small-cell lung cancer. Lung Cancer 2004; 46:255-261.
77. Chiu CH, Tsai CM, Chin YM, et al. Gefitinib is active in patients with brain metastases from non-small cell lung cancer and response is related to skin toxicity. Lung Cancer 2005; 47:129-138.
78. Cappuzzo F, Ardizzoni A, Soto-Parra H, et al. Epidermal growth factor receptor targeted therapy by ZD 1839 (Iressa) in patients with brain metastases from non-small cell lung cancer (NSCLC). Lung Cancer 2003; 41:227-231.
79. Ceresoli GL, Cappuzzo F, Gregorc V, et al. Gefitinib in patients with brain metastases from non-small cell lung cancer: a prospective trial. Ann Oncol 2004; 15:1042-1047.
80. Stemmler HJ, Weigert O, Krych M, et al. Brain metastases in metastatic non-small cell lung cancer responding to single-agent gefitinib: a case report. Anticancer Drugs 2005; 16:747-749.